JULIANNA KIRYLKA: Open Payments
NPI 1851085823 · WHITESBORO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$296 in 15 payments from 9 companies in 2025. Trend: 2023 $19 · 2024 $145 · 2025 $296
Food & beverage: $296
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $54 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| AstraZeneca Pharmaceuticals LP | 2 | $45 |
| Lundbeck LLC | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Edwards Lifesciences Corporation | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| PFIZER INC. | 1 | $20 |
| Lilly USA, LLC | 1 | $14 |
Products named: SHINGRIX, REXULTI, Ozempic, FARXIGA, INJECTAFER, Auvelity, ELIQUIS, Rybelsus.
Industry payments across NY — which companies pay providers there.
